ACOG Practice Bulletin. 2001; no. 26.

Baird D. Mode of action of medical methods of abortion. JAMWA. 2000; 35(3): S121-126.

Barbosa RM, Arilha M. The Brazilian experience with Cytotec. Studies in Family Planning. 1993; 24(4): 236-240.

Bebbington MW, Kent N, Lim K, Gagnon A, Delisle M, Tessier F, Wilson RD. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet. Gynecol. 2002; 187(4): 853-857.

Benson J, Clark KA, Gerhardt A, Randall L, Dudley S. Early abortion services in the United States: Ensuring service availability, remaining on the cutting edge of technology, and responding to client demand. Chapel Hill, NC: IPAS, 2001.

Blanchard K, Winikoff B, Ellertson C. Misoprostol used alone for the termination of early pregnancy: A review of the evidence. Contraception 1999; 59: 209-217.

Blanchard K, Clark S, Winikoff B, Gaines G, Kabani G, Shannon C. Misoprostol for women's health: A review. Am J Obstet Gynecol. 2002; 99(2): 316-332.

Boonstra H. Mifepristone in the United States: Status and Future. The Guttmacher Report on Public Policy. 2002: 4-7.

Bugalho A, Mocumbi S, Faúndes A, David E. Termination of pregnancies of <6 weeks gestation with a single dose of 800 µg of vaginal misoprostol. Contraception. 2000; 61: 47-50.

Bygdeman M, Gemzell K, Marions L. Medical termination of early pregnancy: The Swedish experience. JAMWA. 2000; 35(3): S195-196.

Carbonell J, Rodrigues J, Aragón S, Velazco A, Tanda R, Sánchez C, Barambio S, Chami S, Valero F. Vaginal misoprostol 1000 µg for early abortion. Contraception 2001; 63: 131-136.

Carbonell Esteve J, Varela L, Velazco L, Cabezas A, Tanda R, Sánchez C. Vaginal misoprostol for late first trimester abortion. Contraception. 1998; 57: 329-333.

Carbonell Esteve J, Varela L, Velazco A., Tanda R, Cabezas E, Sánchez C. Early abortion with 800 µg of misoprostol by the vaginal route. Contraception. 1999; 59; 219-225.

Clark S, Ellertson C, Winikoff B. Is medical abortion acceptable to all American women: The impact of sociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion. JAMWA. 2000; 35(3): S177-182.

Costa S, Vessey M. Misoprostol and illegal abortion in Rio de Janeiro, Brazil. Lancet. 1993; 341: 1258-1261.

Coyaji K. Early medical abortion in India: Three studies and their implications for abortion services. JAMWA. 2000; 35(3): S191-194.

Creinin MD, Schwartz JL, Guido RS, Pymar HC. Early Pregnancy Failure-Current Management Concepts. Obstetrical and Gynecological Survey. 2001; 56(2): 105-113.

Creinin MD. Medical abortion regimens: historical context and overview. Am J Obstet Gynecol. 2000; 183: S3-S9.

Creinin M, Pymar H. Medical abortion alternatives to mifepristone. JAMWA. 2000; 35(3): S127-132.

Creinin MD, Carbonell JL, Schwartz JL, Varela L, Tanda R. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception. 1999; 59(1): 217-221.

Ellertson C, Elul B, Winikoff B. Can women use medical abortion without medical supervision? Reproductive Health Matters. 1997; 9: 149-161.

Ellertson C, Waldman S. The Mifepristone-Misoprostol Regimen for Early Medical Abortion. Current Women's Health Reports 2001; 1: 184-190.

Elul B, Pearlman E, Sorhaindo A, Simonds W, Westhoff C. In-depth interviews with medical abortion clients: Thoughts on the method and home administration of misoprostol. JAMWA. 2000; 35(3): S169-172.

Ewart W, Winikoff B. Toward safe and effective medical abortion. Science. 1998; 281: 520-521.

Finer L, Henshaw S. Abortion Incidence and Services in the United States in 2000. Perspectives on Sexual and Reproductive Health. 2003; 35(1): 6-15.

Glick E. Surgical Abortion. Reno, NV: West End Women's Medical Group, 1998.

Harper C, Ellertson C, Winikoff B. Could American women use mifepristone-misoprostol pills safely with less medical supervision? Contraception 2002; 65(2): 133-142.

Harvey SM, Sherman CA, Bird ST, Warren J. Understanding Medical Abortion: Policy, Politics, and Women's Health. Eugene, OR: Center for the Study of Women in Society, 2002.

Henshaw SK, Finer LB. The accessibility of abortion services in the United States, 2001. Perspectives on Sexual and Reproductive Health. 2003; 35(1): 16-24.

Jain JK, Dutton C, Harwood B, Meckstroth KR, Mishell DR. A prospective randomize, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Human Reproduction 2002; 17(6): 1477-1482.

Jain J, Kuo J, Mishell D. A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Am J Obstet. Gynecol. 1999; 93(4): 571-575.

Jones RK, Darroch JE, Henshaw SK. Patterns in the socioeconomic characteristics of women obtaining abortion in 2000-2001. Perspectives on Sexual and Reproductive Health. 2002; 34(5): 226-235.

Jones R, Henshaw S. Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden. Perspectives on Sexual and Reproductive Health. 2002; 34(3): 154-161.

Kahn J, Becker B, MacIsaac L, et al. The efficacy of medical abortion: a meta-analysis. Contraception. 2000; 61:29-40.

Kruse B. Advanced practice clinicians and medical abortion: Increasing access to care. JAMWA. 2000; 35(3): S167-168.

Melbye M, Wohlfahrt J, Olsen JH, et al. Induced abortion and the risk of breast cancer. N Engl J Med. 1997; 336(2): 81-85.

National Abortion Federation. Early medical abortion with mifepristone and other agents: Overview and protocol recommendations. Washington, DC: NAF, 2002.

Newhall E, Winikoff B. Abortion with Mifepristone and Misoprostol: Regimens, Efficacy, Acceptability and Future Directions. Am J Obstet Gyncol. 2000; 183(2): S44-53.

Ngai SW, Tang OS, Chan YM, Ho PC. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: Efficacy and acceptability. Human Reproduction. 2000; 15(5): 1159-1162.

Pymar H, Creinin M. Alternatives to mifepristone regimens for medical abortion. Am J Obstet Gyncol. 2000; 183(2). S54-64.

Rodger MW, Baird DT. Blood loss following induction of early abortion using mifepristone (RU 486) and a prostaglandin analog (gemeprost). Contraception. 1997; 56(3): 165-168.

Rosing M, Archbald C. The knowledge, acceptability, and use of misoprostol for self-induced medical abortion in an urban US population. JAMWA. 2000; 35(3): S183-185.

Schaff E, Fielding S. A comparison of the Abortion Rights Mobilization and Population Council trials. JAMWA. 2000; 35(3): S137-140.

Schaff E, Fielding SL, Westhoff C, Ellertson C, Eisinger Stadalius LS, Fuller L. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. JAMWA. 2000; 284(15): 1948-1953

Shangchun, W. Medical abortion in China. JAMWA. 2000; 35(3): S197-199.

Spitz I, Bardin C, Benton L, and Robbins A. Early Pregnancy Termination with Mifepristone and Misoprostol in the United States. N Eng J Med. 1998; 338: 1241-1247.

Stewart FH, Wells ES, Flinn SK, Weitz TA. Early medical abortion: Issues for practice. San Francisco, CA: UCSF, Center for Reproductive Health Research and Policy, 2000.

Tang OS, Miao BY, Lee SWH, Ho PC. Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: Efficacy and acceptability. Human Reproduction 2002; 17(3): 654-658.

Tang OS, Ho PC. Pilot study on the use of sublingual misoprostol for medical abortion. Contraception 2001; 64: 315-317.

Ulmann A. The development of mifepristone: A pharmaceutical drama in three acts. JAMWA. 2000; 35(3): S117-120.

Von Hertzen H. Research on regimens for early medical abortion. JAMWA. 2000; 35(3): S133-136.

World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ. 1993; 307 (6903): 532-537.

¿Preguntas? Si usted tiene preguntas sobre el aborto con medicamentos, favor de visitar la sección de preguntas mas frecuentes (PMF).

Si tiene sugerencias o preguntas sobre este sitio web, por favor contacte a: 

Your access and use of this website is subject to certain terms of use. By viewing web pages in this site, you accept, without limitation or qualification, these terms.

Read our privacy statement.